close
  • Mega Menu Column
    • Facebook
    • Twitter
    • LinkedIn
    • Instagram
    • Donate
  • Home
  • About Us
    • Mission/Overview
    • Our Team
      • Board of Directors
      • Medical Advisors
      • Dental Advisory Council
      • Staff & Coaches
    • Financials
    • Contact Us
  • Living With P/P
    • Understanding P/P
    • All About Pemphigus (Patient Edition)
    • Pemphigoid
    • Diagnosis
    • Treatments
    • Rituxan
    • Find a Doctor
    • Peer Support
      • Patient Education Series
      • Discussion Forum
      • Local Support
    • My Story
    • Ask A Coach
    • Discussion Forum
  • Research
    • Research Grants
    • Clinical Trials
    • Natural History Study (Patient Registry)
    • Clinically Speaking
      • All About Pemphigus (Physician Edition)
      • Pemphigoid
      • Treatments
      • Complications & Side Effects
      • Risk Factors
      • Diagnostic Testing
      • Current Consensus of Disease Outcomes
      • Prevention & Psychology
  • Get Involved
    • Patient Education Conference
    • Healing Heroes
    • Volunteer
    • Awareness
    • Support The IPPF
      • Make A Donation
      • Healing Heroes
      • Planned Giving
      • Other Ways To Give
    • Continuing Medical Education
    • Peer Support
      • Patient Education Series
      • Rare Connect
      • Ask A Coach
      • Local Support
  • News
    • PemPress
    • Quarterly
    • Events
    • The Coaches Corner
  •  Facebook
  •  Twitter
  •  Instagram
  • DONATE
Pemphigus Pemphigoid Foundation logoPemphigus Pemphigoid Foundation logo
  • Menu
  • About Us
    • Mission/Overview
    • Our Team
      • Board of Directors
      • Medical Advisors
      • Dental Advisory Council
      • Staff & Coaches
    • Financials
    • Employment
    • Contact Us
  • Living With P/P
    • Understanding P/P
    • All About Pemphigus (Patient Edition)
    • Pemphigoid
    • Diagnosis
    • Treatments
    • Rituxan
    • Find a Doctor
    • Prescription Assistance
    • Peer Support
      • Patient Education Series
      • Discussion Forum
      • Local Support
    • My Story
    • Ask A Coach
    • Discussion Forum
  • Research
    • Research Grants
    • Clinical Trials
      • What is it?
      • Should I Volunteer?
      • What are my rights?
      • Definitions
    • Natural History Study (Patient Registry)
    • Clinically Speaking
      • All About Pemphigus (Physician Edition)
      • Pemphigoid
      • Treatments
      • Complications & Side Effects
      • Risk Factors
      • Diagnostic Testing
      • Current Consensus of Disease Outcomes
      • Prevention & Psychology
  • Get Involved
    • Patient Education Conference
    • Healing Heroes
    • Advocacy
      • Becoming a Self Advocate
      • Advocacy in Action!
      • Advocacy Tools and Resources
    • Awareness
    • Support The IPPF
      • Ways to Support
      • Make A Donation
      • Planned Giving
      • Volunteer
    • Continuing Medical Education
    • Peer Support
      • Patient Education Series
      • Discussion Forum
      • Local Support
      • Ask A Coach
  • News
    • PemPress
    • Quarterly
    • Events
    • The Coaches Corner

Rituxan Shown as Superior in Achieving Sustained PV Remission

By Patrick Dunn,

Return to Previous Page | PemPress Home

Posted by Patrick Dunn

On June 13, 2019
Genentech logo

Genentech announced this week that positive top line results from the Roche-sponsored Phase III PEMPHIX study evaluating the efficacy and safety of Rituxan® (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris (PV). The study met the primary endpoint, and demonstrated that Rituxan is superior to MMF in achieving sustained complete remission.

“The PEMPHIX study provides additional clinical evidence for the use of Rituxan for the treatment of pemphigus vulgaris,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “These data also demonstrated that Rituxan may provide complete remission rates and successful tapering of corticosteroid therapy that is superior to MMF in adults with pemphigus vulgaris.”

Read the full press release.

  • Facebook
  • Twitter
  • Google+
  • Pinterest
  • LinkedIn

Related

Patrick Dunn
Patrick Dunn
Communications Manager @ International Pemphigus Pemphigoid Foundation
Patrick Dunn is the Communications Manager at the IPPF. Originally from New York, Patrick holds an MFA in Creative Writing and Literature from Stony Brook University and a BS in Business Administration from Villanova University. Outside of work, he can usually be found working on a novel, playing music, or exploring Sacramento with his wife and daughter.

Tagged:pemphiguspemphigus vulgarisrituxanrituximabtreatment

Return to Previous Page | PemPress Home

Post navigation

← PreviousNORD and Trio Health Publish New Book to Provide Critical Patient Insights Into the Burden of Living With and Treating Rare Diseases
NextThe IPPF Receives Grant from Sy Syms Foundation to Accelerate Diagnosis Times →

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • P/P Awareness Campaign
  • Disease Registry
  • Ask A Coach
  • Patients & Caregivers
  • For Medical Professionals
  • Clinical Trials
  • Treatments
  • @healourskin December 13, 2019

    If you live in the Southern New Jersey/Philadelphia area, register today to attend the first support group meeting… twitter.com/i/web/status/1…

  • @healourskin December 9, 2019

    We earned a Platinum Seal of Transparency by sharing the metrics that matter most! Check out our updated… twitter.com/i/web/status/1…

  • @healourskin December 7, 2019

    The IPPF recently presented at @WesternUNews to students in the College of Dental Medicine and College of Optometry… twitter.com/i/web/status/1…

  • @healourskin December 6, 2019

    There's still time to register for the upcoming Austin support group meeting on December 14th. Register today!… twitter.com/i/web/status/1…

  • @healourskin December 5, 2019

    Thank you to everyone that stopped by our booth at the @GNYDM and learned about the IPPF’s #BiopsiesSaveLives campa… twitter.com/i/web/status/1…

  • Volunteer
  • Careers
  • Donate
  • News
  • PemPress
  • Forums
  • Contact

About IPPF

The International Pemphigus & Pemphigoid Foundation’s most important objectives are to provide patients and doctors worldwide with information about pemphigus and pemphigoid, and to provide patients and their caregivers much needed comfort and support so they can continue to live active, productive lives.
Read more »

Contact Us

International Pemphigus & Pemphigoid Foundation
1331 Garden Highway, Ste 100
Sacramento, CA 95833
United States of America

info@pemphigus.org
(855) 473-6744
(916) 922-1298

© 2017 International Pemphigus & Pemphigoid Foundation · All rights reserved.
Privacy Policy | Terms of Use | Sitemap
Website design and implementation by Uptown Studios.
en English
ar العربيةbn বাংলাzh-CN 简体中文en Englishfr Françaisde Deutschel Ελληνικάiw עִבְרִיתhi हिन्दीit Italianoja 日本語fa فارسیpt Portuguêspa ਪੰਜਾਬੀru Русскийes Españolth ไทยvi Tiếng Việt

Cookies

Our site uses cookies. Find out more.